Urology News: Breaking Urology News, Comments and Articles.

Cancer Network Introduces Three New Features

NORWALK, Conn., May 23, 2013 /PRNewswire/ -- UBM Medica US announces that Cancer Network, one of the leading online destinations for Oncologists, has introduced three new serial features in addition to its traditional review articles and expert commentaries. Among the new features are: How an Expert Approaches It: Clinical thought leaders discuss how they handle a difficult tumor type, ther...

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Trial Nearing Its End

The firm is currently offering da Vinci robot lawsuit evaluations to those who have suffered serious da Vinci surgery complications during robotic surgery procedures. (PRWEB) May 23, 2013 A da Vinci surgical robot trial in Washington State was set to enter jury deliberations on May 22.* The Rottenstein Law Group LLP, which represents clients in surgical robot lawsuits, notes that this is the firs...

Professionals and Patients Increasingly Confused by Guidance on Screening for Risk of Prostate Cancer

WASHINGTON, May 23, 2013 /PRNewswire-USNewswire/ -- Representing the interests of the 240,000 American men who are at risk each year for a diagnosis of prostate cancer, and the over 2 million men living today who have been diagnosed with this deadly form of cancer, the membership of the Prostate Cancer Roundtable is increasingly concerned by the utterly confusing guidance being offered –...

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at the upcoming American Society of Clinical Oncology ("ASCO") annual meeting, which will be held May 31 to June 4, 2013, in Chicago. Abstract # 5062:...

NAACCR Enhances Already Powerful Cancer Research Tool by Adding New Data

The North American Association of Central Cancer Registries (NAACCR, Inc.) has released the latest edition of its publication Cancer in North America (CINA) which includes, for the first time, stage at diagnosis for 5 major cancer sites. Springfield, IL (PRWEB) May 23, 2013 Today’s release of Cancer in North America (CINA): 2006-2010 provides researchers and health professionals with the most d...

OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer

BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the seventh...

Direct Digital, LLC Names Dr. David Katz, M.D. As Chief Scientific Advisor

CHARLOTTE, N.C., May 23, 2013 /PRNewswire/ -- Direct Digital, LLC, one of the nation's leading health and wellness product development and marketing companies, is pleased to announce it has selected and partnered with world-renowned physician, Dr. David Katz. Dr. Katz will join the organization as its Chief Scientific and Medical Advisor. Direct Digital is the creator of such leading supplement br...

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.

New overactive bladder drug approved for use in Scotland

A new treatment for overactive bladder has been approved for use by the NHS in Scotland, with England and Wales set to follow suit.

Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13

TORONTO, ONTARIO -- (Marketwired) -- 05/23/13 -- Editors Note: There is a photo associated with this press release. Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased to announce that it has added a third site and first U.S. site, to its Phase I clinical trial, with the first patient beginning treatment this week with anti-...

La Jolla Pharmaceutical Company Releases Data Indicating GCS-100 May Improve Renal Function

SAN DIEGO, CA -- (Marketwired) -- 05/23/13 -- La Jolla Pharmaceutical Company (OTCBB: LJPC) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting galectin proteins, released data today detailing the ability of lead product candidate GCS-100 to improve renal function. The retrospective analysis details the positive effect that GCS-100 treatment had on the estimated glom...

Researchers Hope To Recycle Kidneys To Help solve Donor Organ shortage

Nearly 20 percent of kidneys that are recovered from deceased donors in the U.S. are refused for transplant due to factors ranging from scarring in small blood vessels of the kidney's filtering units to the organ going too long without blood or oxyge...

Mayo Clinic genomic analysis lends insight to prostate cancer

(Mayo Clinic) Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear o...

Using big data to identify prostate cancers and best treatments

(Case Western Reserve University) Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western...

Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications

The Firm is currently investigating legal claims on behalf of individuals who allegedly suffered da Vinci surgery complications in procedures involving the da Vinci Surgical System. New York, New York (PRWEB) May 22, 2013 Jury deliberations are now underway in Washington State Court for the nation’s first trial involving a da Vinci lawsuit, Bernstein Liebhard LLP reports. According to filings...

Dr. Christopher Porter is recognized among Castle Connolly's Top Doctors® for Seattle, WA region in 2013.

SEATTLE, May 22, 2013 /PRNewswire-USNewswire/ -- Castle Connolly Medical Ltd., America's trusted source for identifying Top Doctors, has selected Seattle's Urology specialist Dr. Christopher Porter for inclusion in its highly selective list of Regional Top Doctors this year. (Photo: http://photos.prnewswire.com/prnh/20130522/DC19388) Castle Connolly Medical Ltd. publishes its list of Castle Co...

Prostate cancer current treatment practices

This expert panel discussed the management strategies for advanced prostate cancer and the treatments that are available for metastatic castration resistant disease. Treatment for metastatic castration resistant prostate cancer (CRPC) has evolved...

Baptist Cardiac & Vascular Institute Receives $1 Million Grant

Baptist Cardiac & Vascular Institute (BCVI) announced today it received a $1 million grant from the Argosy Foundation to establish the BCVI Innovation Research Fund. The grant will support original clinical research by providing seed money so Institute physicians and staff can pursue the discovery of new treatments, methods and approach...

Five Transplants in 24 Hours Sets Packard Children’s Record

* First time hospital has transplanted five patients in such a short period of time * Today (22), at one-month anniversary, doctors announce all five patients are doing well * Two livers, two kidneys and a heart were all transplanted For the transplant teams at Lucile Packard Children’s Hospital at Stanford, it was a busy day...

Detecting Prostate Cancer In Urine

Lee Rannals for redOrbit.com – Your Universe Online University of California, Irvine researchers recently wrote in the Journal of the American Chemical Society that they have found a safe and inexpensive way to identify clinically usable markers for prostate cancer in urine. The team's new early screening method for prostate cancer could also potentially be used to detect bladder and multiple...

Stryker Metal Hip Recall: Lieff Cabraser Provides Answers to Hip Replacement Patients

Wendy Fleishman of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that the firm issued today a list of answers to frequently asked questions (FAQ) from hip replacement patients who received the Stryker Rejuvenate or Stryker ABG II hip implant. "We wish to provide patients with the recalled Stryker metal...

Chemists devise inexpensive, accurate way to detect prostate cancer

Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical...

TheraCoat Has Completed a Capital Raising of $7M led by Pontifax and Chaim Hurvitz's CHealth Fund

TheraCoat Ltd. (TheraCoat), a clinical stage specialty pharmaceutical company focused on innovative drug-delivery solutions for the treatment of intra-cavital diseases, announces today the completion of a successful capital raise of $7M from private investors and venture Funds, both in Israel and abroad. Amongst the investors are Pontifax, and Chaim Hurvit...

New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation System.  Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented today at...